Maria Darland, MD
Rheumatology · Alexandria, VANPI 1346421351
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 282 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Johnson & Johnson at 30.8% of the total.
Across 282 payments — averaging $22.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Amgen$911
- AbbVie$622
- UCB, Inc.$602
- Novartis$314
- Pfizer$265
- plus $2K from 23 others
What the payments were for
- Food & beverage$6,08398%
- Education$1472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 80 | $1,917 |
| Amgen(2 entities) | 43 | $911 |
| AbbVie | 39 | $622 |
| UCB, Inc. | 24 | $602 |
| Novartis | 13 | $314 |
| Pfizer | 11 | $265 |
| GSK | 12 | $228 |
| Boehringer Ingelheim | 7 | $187 |
| Lilly USA, LLC | 8 | $173 |
| Radius Health, Inc. | 7 | $161 |
| E.r. Squibb & Sons, L.L.C. | 7 | $148 |
| Genentech USA, Inc. | 5 | $97 |
| Mallinckrodt Hospital Products Inc. | 3 | $82 |
| Aurinia Pharma U.S., Inc. | 4 | $78 |
| Sandoz | 2 | $51 |
| AstraZeneca | 2 | $51 |
| Boston Scientific | 1 | $51 |
| Regeneron Healthcare Solutions, Inc. | 2 | $46 |
| Fresenius Kabi USA, LLC | 2 | $37 |
| ANI Pharmaceuticals, Inc. | 1 | $31 |
| Antares Pharma, Inc. | 1 | $23 |
| Bristol Myers Squibb | 1 | $23 |
| Mindray DS USA, Inc. | 1 | $22 |
| Medtronic | 1 | $22 |
| Fidia Pharma USA Inc. | 1 | $22 |
| Sobi, Inc | 1 | $21 |
| Pharming Healthcare, Inc. | 1 | $17 |
| Merck | 1 | $14 |
| Sanofi | 1 | $13 |
How this compares
$6,230 in reported general payments places this provider in the 65th percentile of 159 rheumatology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 83 | $606,698 |
| StelaraUstekinumab | 18 | $420,942 |
| EnbrelEtanercept | 36 | $342,575 |
| Skyrizi PenRisankizumab-Rzaa | 14 | $286,071 |
| Orencia ClickjectAbatacept | 24 | $148,708 |
| Enbrel SureclickEtanercept | 16 | $148,121 |
| Cosentyx Sensoready PenSecukinumab | 14 | $106,837 |
| BenlystaBelimumab | 21 | $100,336 |
| Hydroxychloroquine Sulfate | 476 | $13,262 |
| Mycophenolate Mofetil | 40 | $7,736 |
| Colchicine | 90 | $5,556 |
| Leflunomide | 66 | $5,469 |
| Diclofenac Sodium | 63 | $4,852 |
| MethotrexateMethotrexate Sodium | 239 | $4,724 |
| Duloxetine Hcl | 231 | $3,606 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,917 | $420,94218 claims |
| AmgenEnbrel | $911 | $342,57536 claims |
| GSKBenlysta | $228 | $100,33621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 159 rheumatology providers in Virginia.
Other rheumatology in Alexandria
- Zuhal ArzomandAlexandria$10K
- Peter LipskyCharlottesville$1.3M
- Kristi MizelleNewport News$1.1M
- Phillip KempfArlington$321K
- Sharukh ShroffDanville$216K
- Michael StrachanRichmond$158K
- Karim MasriRichmond$147K
- Michael CannonVirginia Beach$145K
- Phong NguyenReston$127K
- Chase CorreiaHampton$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.